Ryvu Therapeutics (RVU) Q3 2025 earnings summary

Executive summary

• Operating revenue for the first nine months of 2025 was PLN 61.9 million, down from PLN 73.6 million year-over-year, mainly due to lower R&D project and subsidy revenues, partially offset by higher sales from collaborations.

• Net loss increased to PLN 83.6 million from PLN 76.4 million year-over-year, driven by lower revenues and a negative impact from NodThera share valuation, partially offset by a positive put option effect related to EIB financing.

• Strategic reorganization, including a 30% workforce reduction and pipeline adjustments, was implemented to extend the cash runway into H2 2026 and focus on key clinical and preclinical programs.

Financial highlights

• Total assets decreased to PLN 255.3 million as of September 30, 2025, from PLN 378.8 million at year-end 2024, mainly due to R&D expenditures.

• Cash and cash equivalents were PLN 89.1 million, down from PLN 160.1 million at year-end 2024.

• Operating expenses for the nine months were PLN 152.7 million, with an operating loss (EBIT) of PLN 90.8 million.

• EBITDA for the period was negative PLN 83.2 million.

• Net cash outflow from operating activities was PLN 86.0 million; investing activities provided PLN 18.2 million.

Outlook and guidance

• Cash position and EIB financing support ongoing operations and planned investments, with a focus on advancing romaciclib and early pipeline projects.

• Future revenues depend on successful commercialization of R&D projects and achieving milestones in existing collaborations.

• The company aims to initiate and execute broad Phase II clinical development for romaciclib, support partnered candidate SEL24, and advance a new program into Phase I.